Skip to main content

Inhibrx Biosciences, Inc.

INBX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002007919

In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 5 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.

Holders of 5% or more of INBX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Inhibrx Biosciences, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of INBX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Perceptive Advisors LLC13G/A9.99%1.49M shares0.00 ppfrom 9.99%May 15, 20262 filingsAug 14, 2026SEC
Viking Global Investors LPSuperinvestorViking Global Investors13G/A9.30%1.38M shares−0.69 ppfrom 9.99%Feb 17, 20263 filingsAug 14, 2026SEC
Morgan Stanley13G7.90%1.16M sharesNewFeb 11, 20261 filingFeb 11, 2026SEC
Kayyem Jon Faiz13D/A7.90%1.15M shares–Feb 26, 20251 filingFeb 26, 2025SEC
Lappe Mark13D/A6.40%925.4K shares–Feb 26, 20251 filingFeb 26, 2025SEC
Bank of America Corp13G5.90%857.3K sharesNewAug 3, 20261 filingAug 3, 2026SEC
Schonfeld Strategic Advisors LLC13G5.33%781.7K sharesNewAug 14, 20261 filingAug 14, 2026SEC
BlackRock, Inc.13G5.30%768.1K shares+0.60 ppfrom 4.70%Feb 4, 20253 filingsJan 21, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

13 Schedule 13D and 13G filings on Inhibrx Biosciences, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on INBX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20265:19 PM ETPerceptive Advisors LLCand 2 others13G/A9.99%1.49M shares0.00 ppfrom 9.99%Jun 30, 2026SEC
Aug 14, 20264:15 PM ETSchonfeld Strategic Advisors LLC13G5.33%781.7K sharesNewJun 30, 2026SEC
Aug 14, 20264:10 PM ETViking Global Investors LPand 10 othersSuperinvestorViking Global Investors13G/A9.30%1.38M shares−0.69 ppfrom 9.99%Jun 30, 2026SEC
Aug 3, 202612:26 PM ETBank of America Corp13G5.90%857.3K sharesNewJun 30, 2026SEC
May 15, 20265:48 PM ETViking Global Investors LPand 10 othersSuperinvestorViking Global Investors13G/A9.99%1.46M shares0.00 ppfrom 9.99%Mar 31, 2026SEC
May 15, 20264:00 PM ETPerceptive Advisors LLCand 2 others13G/A9.99%1.46M shares–Mar 31, 2026SEC
Feb 17, 20264:26 PM ETViking Global Investors LPand 11 othersSuperinvestorViking Global Investors13G/A9.99%1.45M shares–Dec 31, 2025SEC
Feb 11, 20261:33 PM ETMorgan Stanleyand 1 other13G7.90%1.16M sharesNewDec 31, 2025SEC
Jan 21, 202612:30 PM ETBlackRock, Inc.13G5.30%768.1K shares+0.60 ppfrom 4.70%Dec 31, 2025SEC
Oct 17, 20256:13 PM ETBlackRock, Inc.13G/A4.70%680.4K shares−1.00 ppfrom 5.70%Below 5%Sep 30, 2025SEC
Feb 26, 20254:26 PM ETKayyem Jon Faizand 1 other13D/A7.90%1.15M shares–Jun 3, 2024SEC
Feb 26, 20254:16 PM ETLappe Mark13D/A6.40%925.4K shares–Sep 12, 2024SEC
Feb 4, 20253:45 PM ETBlackRock, Inc.13G5.70%831.8K sharesNewDec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Inhibrx Biosciences, Inc. shares.

No Form 144 notices for Inhibrx Biosciences, Inc. are on file.